Latest Strategic Acquisitions News

Civmec Limited reported solid FY2025 financials with revenue surpassing A$810 million and a strengthened order book of A$1.25 billion, underpinned by its strategic acquisition of Luerssen Australia.

Civmec Limited reported a 21.6% drop in revenue and a 34% fall in net profit for FY2025, reflecting the impact of completed contracts. Despite this, the company maintained steady margins and increased its cash reserves, signaling resilience and ongoing growth potential.

Steadfast Group reported a robust FY25 with underlying NPAT rising 17.2% to $295.5 million, driven by strong organic growth and strategic acquisitions in the US and UK. The insurer broker continues to invest in technology and international expansion while raising dividends.

Steadfast Group has reported a robust 17.2% increase in underlying net profit after tax for FY25, alongside a 14% rise in its fully franked final dividend, underpinned by both organic growth and strategic acquisitions.

Steadfast Group Limited reported a robust 47% jump in statutory net profit for FY25, boosted by a significant one-time gain from acquiring Rothbury Group. The company also declared a fully franked final dividend of 11.7 cents per share.

ARC Funds Limited posted a $2.45 million loss for FY2025, driven by strategic investments and increased transaction costs as it expands its funds management platform.

BTC Health Limited reported a robust 25% revenue increase in FY25, driven by strategic contract wins and expanded product offerings across critical medical sectors. The company’s positive EBITDA and new partnerships position it well for continued growth in FY26.

BTC Health reports a strong FY25 with a $4 million statutory profit, boosted by a $5 million contract and strategic acquisition. The company eyes further growth in FY26 with new product launches and expanded market reach.

BTC Health Limited reported a remarkable 277% increase in profit after tax to nearly $4 million for FY25, driven by significant fair value gains on its healthcare investments and key contract wins.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

McMillan Shakespeare Limited reported a 14.1% rise in statutory net profit after tax to $95.3 million for FY25, alongside a fully franked final dividend of 77 cents per share. The company’s strategic investments in digital platforms and acquisitions underpin its growth trajectory.

SSH Group Limited reported a 7% revenue decline and a 21% drop in profit after tax for FY2025, while net tangible assets per share doubled amid strategic acquisitions.